TABLE 2.
List of antibodies used throughout this study
| Antibody | Target | Concentration (μg/mL) | Source |
|---|---|---|---|
| 1 | NTDa | 1 | Humoral Immunology Unit—Institut Pasteur (39) |
| 10 | S2 | 1 | |
| 18 | NTD | 1 | |
| 20 | NTD | 1 | |
| 21 | NTD | 1 | |
| 32 | NTD | 1 | |
| 40 | NTD | 1 | |
| 45 | NTD | 1 | |
| 53 | NTD | 1 | |
| 69 | NTD | 1 | |
| 71 | NTD | 1 | |
| 83 | NTD | 1 | |
| 105 | NTD | 1 | |
| 114 | NTD | 1 | |
| 118 | NTD | 1 | |
| 127 | NTD | 1 | |
| 129 | RBDa | 1 | |
| Sotrovimab (VIR-7831) | RBD | 1 | CHR Orleans |
| Cilgavimab (AZD1061) | RBD | 1 | |
| Tixagevimab (AZD8895) | RBD | 1 | |
| Imdevimab (REGN10897) | RBD | 1 | |
| Bebtelovimab (LY-CoV1404) | RBD | 1 | (40) |
| Anti-IgG AF647 | Human-IgG Fc | 3.3 | Thermo Fisher Scienfitic |
a
NTD, N-terminal domain; RBD, receptor-binding domain.